Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28490180 | 0.96 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3DAOSKP2 | |
| SCHEMBL10304852 | 0.88 | SKP2 (0.61) | SLC6A2SLC6A4SLC6A3DAOSKP2 | |
| SCHEMBL19309413 | 0.84 | HTR2A (0.53) | SLC6A2SLC6A4SLC6A3DAOSKP2 | |
| SCHEMBL9921243 | 0.83 | DAO (0.50) | SLC6A2SLC6A4SLC6A3DAOSKP2 | |
| SCHEMBL23903966 | 0.83 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3DAOTP53 | |
| SCHEMBL6953517 | 0.82 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3DAOPTGS1 | |
| SCHEMBL530305 | 0.82 | CNR1 (0.48) | DAOCNR1CNR2NPC1TP53 | |
| SCHEMBL16950793 | 0.81 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3DAOPTGS1 | |
| Ammonia Solution, Strong SCHEMBL6193068 | 0.80 | CNR1 (0.47) | DAOCNR1CNR2NPC1TP53 | |
| SCHEMBL17971122 | 0.79 | ESR1 (0.54) | SLC6A2SLC6A4SLC6A3DAOPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021179274-A1 | ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS | SUZHOU ZANRONG PHARMA LTD. (CN) | 2021-09-16 | — | — | WO | disclosed |
| WO-2020139960-A1 | GALECTIN-3 INHIBITING C-GLYCOSIDES | GLYCOMIMETICS, INC (US) | 2020-07-02 | — | — | WO | disclosed |
| US-8309587-B2 | Piperidine and piperazine phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7462611-B2 | inhibitor of HCV NS5B polymerase; to treat infections caused by hepatitis C virus; 3-(1,1-Dioxo-1,4-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-4-hydroxy-1-(3-methyl-butyl)-pyrrolo[1,2-b]pyridazin-2-one | ANADYS PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008051637-A2 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007150001-A1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2003101382-A2 | COMPOUNDS USEFUL IN THE TREATMENT OF ANTHRAX AND INHIBITING LETHAL FACTOR | MERCK & CO., INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, TRPA1, TRPV5 | SLC6A2 278/4885SLC6A4 208/4885SLC6A3 224/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | SLC6A2 677/4885SLC6A4 1386/4885SLC6A3 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.